PURPOSE: Solitary brain metastasis (MET) and glioblastoma multiforme (GBM) can appear similar on conventional MRI. The purpose of this study was to identify MR perfusion and diffusion-weighted biomarkers that can differentiate MET from GBM, using voxel-based analysis.
MATERIALS AND METHODS: In this retrospective study, patients were included if they met the following criteria: underwent resection of a solitary enhancing brain tumor and had preoperative 3.0T MRI encompassing DTI, dynamic contrast-enhanced (DCE) and DSC perfusion. Using coregistered images, voxel-based FA, MD, Ktrans and rCBV values were obtained in the enhancing tumor and non-enhancing peritumoral T2 hyperintense region (NET2). Data were analyzed by logistic regression and analysis of variance. Receiver operating characteristic (ROC) analysis was performed to determine the optimal parameter(s) and threshold(s) for predicting GBM vs. MET.
RESULTS: Twenty-three patients (14 M, age: 32-78 y/o) met inclusion criteria. Pathology revealed 13 GBM’s and 10 MET’s. In the enhancing tumor, rCBV, Ktrans, and FA were significantly higher (p<0.0001) in GBM than in MET, whereas MD was significantly lower (p<0.0001) in GBM than in MET. In the NET2, rCBV and FA were significantly higher (p<0.0001) in GBM than in MET, but MD and Ktrans were significantly lower (p<0.0001) in GBM compared to MET. The best discriminative power was obtained in NET2 (not in enhancing tumor) from a combination of rCBV > 0.78, FA > 0.12, MD < 1700 x 10−6 mm2/s, and Ktrans < 0.25 1/min, resulting in an AUC of 0.92 superior to any individual or combination of other classifiers (Figure 1).
CONCLUSIONS: Our multiparametric MRI model is able to distinguish GBM from MET by using a combination of rCBV, Ktrans, FA, and ADC in NET2 with an AUC of 0.92 superior to any individual or combination of other classifiers.